Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

About this update from Cytokinetics, Incorporated

European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first commercial European launch of MYQORZO® (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction. Marking the first of several planned European launches, the availability of MYQORZO in Germany follows the European Commission approval in February 2026. The approval was based on positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with oHCM, demonstrating robust efficacy, safety, and clinically meaningful benefits across symptoms, exercise capacity, hemodynamics, and biomarker endpoints.1 These clinical results were published in the New England Journal of Medicine. “Bringing MYQORZO to Europe marks an exciting new chapter for Cytokinetics as we extend our reach to more patients with symptomatic oHCM,” said Joseph Dagher, Senior Vice President and Head of Europe, Cytokinetics. “This milestone further strengthens our leadership in muscle biology and reinforces Cytokinetics’ commitment to the global HCM community.” MYQORZO was previously approved in December 2025 by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms, and by the China National Medical Products Administration (NMPA) for the treatment of adults with NYHA class II-III oHCM, to improve exercise capacity and symptoms. “The latest advancement in myosin inhibition brings a new treatment option into our clinical practice in Europe and Germany to help patients with symptomatic oHCM,” said Prof. Benjamin Meder, FESC, Chair of Precision Digital Health, Head of the Institute for Cardiomyopathies Heidelberg and Deputy Medical Director, Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg. The results from SEQUOIA-HCM showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo...

View stock analysis, news, and events for Cytokinetics, Incorporated